Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update
نویسندگان
چکیده
منابع مشابه
Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update.
In current practice, gadolinium-based contrast agents have been considered safe when used at clinically recommended doses in patients without severe renal insufficiency. The causal relationship between gadolinium-based contrast agents and nephrogenic systemic fibrosis in patients with renal insufficiency resulted in new policies regarding the administration of these agents. After an effective s...
متن کاملCadmium toxicity and treatment: An update
Cadmium poisoning has been reported from many parts of the world. It is one of the global health problems that affect many organs and in some cases it can cause deaths annually. Long-term exposure to cadmium through air, water, soil, and food leads to cancer and organ system toxicity such as skeletal, urinary, reproductive, cardiovascular, central and peripheral nervous, and respiratory systems...
متن کاملA Novel Gadolinium-Based Contrast Agent Targeted to Cathepsin-D
slice images of Gd-DTPA, Gd-DOTACAT and 10% BSA at 37oC at 9.4T. Figure 2. Relaxation rate (R1 = 1/T1) as a function of concentration. Gd-DOTACAT has a greater relaxivity 6.9 (mM s) than clinically used Gd-DTPA (Magnevist®) of 3.2 (mM s). Figure 3. Signal intensity plots from 3 regions of interest: brain tissue, cerebral and non-cerebral blood vessels. There was an increase in signal intensity ...
متن کاملExtracellular gadolinium-based contrast media: an overview.
Increasing use is made of extracellular MRI contrast agents that alter the image contrast following intravenous administration; they predominantly shorten the T1 relaxation time of tissues. The degree and location of these changes provide substantial diagnostic information. However gadolinium-based contrast agents (Gd-CA) are not inert drugs. They may cause acute non-renal adverse reactions (e....
متن کاملGadolinium-DTPA: A New Contrast Agent
Gadolinium (Gd)-DTPA-dimeglumine (tradename: Magnevist?) is the first commercially available contrast agent for magnetic resonance tomography (MRT). As a result of the very favourable results from preclinical and clinical investigations Magnevist? was granted a product license for cranial and spinal MRT in the Federal Republic of Germany in early February this year. Magnevist? is a paramagnetic...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Neuroradiology
سال: 2015
ISSN: 0195-6108,1936-959X
DOI: 10.3174/ajnr.a4615